Quarterly report pursuant to Section 13 or 15(d)

License Revenue (Details)

v3.22.1
License Revenue (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Aug. 31, 2020
Jul. 31, 2018
Jun. 30, 2018
Mar. 31, 2022
Mar. 31, 2021
Licensing Arrangements          
Total revenue       $ 20 $ 209
Pharmbio Korea Inc | Licensing agreements for development and commercialization          
Licensing Arrangements          
Upfront payment     $ 3,000    
Commercialization milestone payments     $ 500    
Time period for written notice to terminate license agreement     180 days    
Pharmbio Korea Inc | Licensing agreements for development and commercialization | Minimum          
Licensing Arrangements          
Time period to form a committee prior to the anticipated date of regulatory approval     6 months    
Pharmbio Korea Inc | Licensing agreements for development and commercialization | Maximum          
Licensing Arrangements          
Royalties on product sales, percentage     20.00%    
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements for development and commercialization          
Licensing Arrangements          
Upfront payment   $ 2,500      
Withholding taxes $ 300 $ 300      
Time period for written notice to terminate license agreement 180 days        
Milestone payment upon regulatory approval $ 3,000        
Milestone payment upon regulatory approval in China 3,000        
Milestone payment upon sales targets reached in China $ 6,000        
Royalty percentage on net product sales in China after milestones met 10.00%        
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements for development and commercialization | Minimum          
Licensing Arrangements          
Time period to form a committee prior to the anticipated date of regulatory approval 6 months        
License revenue          
Licensing Arrangements          
Total revenue       20  
License revenue | Licensing agreements for development and commercialization          
Licensing Arrangements          
Withholding taxes     $ 500    
License revenue | Pharmbio Korea Inc          
Licensing Arrangements          
Total revenue       $ 20